Actively Recruiting
A Phase 3 Study of Interferon Gamma Treatment for Ventilator-Acquired Pneumonia in ICU Patients Evaluating the Effect on Mechanical Ventilation Duration
Led by Hospices Civils de Lyon · Updated on 2026-07-06
132
Participants Needed
9
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
The trial investigates the use of human recombinant interferon gamma IFN in patients in intensive care who develop ventilator-associated pneumonia VAP after severe injury, infection, trauma, or burns. These patients often experience immune system problems that increase susceptibility to infections like VAP. This Phase 3 study aims to assess whether IFN can affect the duration of mechanical ventilation after the first VAP episode in patients with low monocyte HLA-DR levels, which indicate immunosuppression. Participants are randomly assigned to receive either IFN or a placebo. The IFN group receives daily subcutaneous injections of 100 micrograms for 5 days, while the placebo group receives an injectable sodium chloride solution. This double-blind, placebo-controlled design compares the two groups to evaluate IFN as an additional treatment alongside antibiotics. Throughout the study, participants are closely monitored for the duration of mechanical ventilation over 28 days from VAP diagnosis. Researchers also assess mortality, microbiological response, intensive care and hospital stay lengths, recurrence of infections, immune cell activity markers, blood counts, and economic impact. Safety and effectiveness data are collected until the study ends, with the trial expected to complete by July 2027.
CONDITIONS
Brief Title
Human Recombinant Interferon Gamma in the Treatment of Ventilator-acquired Pneumonia in ICU Patients
Research Team
A
Anne-Claire LUKASZEWICZ, Pr
C
Camille BOUCHENY
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here